A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Inclusion Criteria:

* Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
* Have a length of disease duration, from first symptom, of less than (\<) 10 years
* Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
* Suboptimal disease control while on a DMT
* Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
* For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria:

* Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
* Inability to complete an Magnetic Resonance Imaging (MRI) procedure
* Known presence of other neurological disorders
* Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
* History or currently active primary or secondary immunodeficiency
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
* History of opportunistic infections
* History or known presence of recurrent or chronic infection
* History of malignancy
* Congestive heart failure
* Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds